Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CBAY | CymaBay Therapeutics, Inc.

Index	RUT	P/E	-	EPS (ttm)	-0.88	Insider Own	0.31%	Shs Outstand	110.36M	Perf Week	-13.71%
Market Cap	1.65B	Forward P/E	-	EPS next Y	-1.35	Insider Trans	-47.71%	Shs Float	104.53M	Perf Month	11.79%
Income	-80.70M	PEG	-	EPS next Q	-0.30	Inst Own	76.30%	Short Float / Ratio	8.58% / 3.51	Perf Quarter	73.40%
Sales	31.00M	P/S	53.23	EPS this Y	4.70%	Inst Trans	-0.92%	Short Interest	8.96M	Perf Half Y	66.10%
Book/sh	1.06	P/B	13.77	EPS next Y	-47.30%	ROA	-41.80%	Target Price	22.17	Perf Year	280.21%
Cash/sh	1.89	P/C	7.71	EPS next 5Y	-	ROE	-104.50%	52W Range	3.15 - 18.20	Perf YTD	132.85%
Dividend	-	P/FCF	-	EPS past 5Y	-8.90%	ROI	-	52W High	-19.78%	Beta	0.34
Dividend %	-	Quick Ratio	12.50	Sales past 5Y	-	Gross Margin	-	52W Low	362.76%	ATR	0.95
Employees	63	Current Ratio	12.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	49.86	Volatility	5.45% 6.49%
Optionable	Yes	Debt/Eq	0.92	EPS Q/Q	97.40%	Profit Margin	-	Rel Volume	0.68	Prev Close	14.64
Shortable	Yes	LT Debt/Eq	0.92	Earnings	Aug 10 AMC	Payout	-	Avg Volume	2.56M	Price	14.60
Recom	1.50	SMA20	-2.64%	SMA50	9.93%	SMA200	53.85%	Volume	1,742,102	Change	-0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-23	Initiated	UBS	Buy	$18
Aug-11-23	Initiated	Guggenheim	Buy	$20
Apr-05-23	Initiated	William Blair	Outperform
Mar-09-23	Initiated	BTIG Research	Buy	$15
Apr-11-22	Resumed	Cantor Fitzgerald	Overweight	$9
Aug-04-20	Reiterated	H.C. Wainwright	Buy	$9 → $13
Jul-31-20	Initiated	Piper Sandler	Overweight	$12
May-26-20	Upgrade	H.C. Wainwright	Neutral → Buy	$9
May-12-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$6
May-12-20	Upgrade	Stifel	Hold → Buy	$4 → $8
May-12-20	Upgrade	ROTH Capital	Neutral → Buy	$15
May-12-20	Upgrade	Raymond James	Mkt Perform → Outperform	$7
May-12-20	Upgrade	Evercore ISI	In-line → Outperform	$15
Mar-13-20	Upgrade	Oppenheimer	Perform → Outperform	$4
Mar-13-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-26-19	Downgrade	ROTH Capital	Buy → Neutral	$22 → $2
Nov-26-19	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-26-19	Downgrade	H.C. Wainwright	Buy → Neutral	$16 → $2
Nov-26-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$20 → $2
Nov-25-19	Downgrade	SunTrust	Buy → Hold

Show Previous Ratings

Sep-21-23 04:39PM	Why CymaBay Therapeutics Stock Is Sinking This Week (Motley Fool)
08:00AM	CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis (GlobeNewswire)
Sep-20-23 01:01AM	Insider Sell: Charles Mcwherter Sells 21,746 Shares of CymaBay Therapeutics Inc (CBAY) (GuruFocus.com)
Sep-15-23 08:00AM	CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-14-23 04:57PM	CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
05:37PM	Loading…
Sep-12-23 05:37PM	Why CymaBay Therapeutics Stock Triumphed Again on Tuesday (Motley Fool)
Sep-11-23 10:15PM	CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +5.48%
06:31PM	Why CymaBay Therapeutics Stock Popped Again Today (Motley Fool)
06:00AM	CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Sep-08-23 04:49PM	Why CymaBay, With 159% Growth This Year, Just Surged For A Second Day Running (Investor's Business Daily) +8.19%
01:12PM	CymaBay (CBAY) Stock Up on Positive Results From PBC Study (Zacks)
11:59AM	Why CymaBay Therapeutics Stock Is Jumping Today (Motley Fool)
11:50AM	Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running (Investor's Business Daily)
Sep-07-23 07:00AM	CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis (PR Newswire) +8.53%
Sep-06-23 04:05PM	CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023 (GlobeNewswire)
04:29PM	Loading…
Aug-28-23 04:29PM	CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-23 08:48AM	CymaBay Therapeutics (NASDAQ:CBAY) shareholder returns have been splendid, earning 236% in 1 year (Simply Wall St.)
Aug-11-23 09:36AM	Twilio upgraded, Sealed Air downgraded: Wall Street's top analyst calls (The Fly)
Aug-10-23 04:04PM	CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase (PR Newswire)
Aug-03-23 04:05PM	CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-17-23 08:50AM	Recent Price Trend in CymaBay Therapeutics Inc. (CBAY) is Your Friend, Here's Why (Zacks)
Jun-30-23 11:50AM	Why Shares of CymaBay Therapeutics Are Soaring Friday (Motley Fool) +39.67%
Jun-24-23 03:19PM	11 Best Medical Stocks Under $10 (Insider Monkey)
Jun-21-23 03:00AM	CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels (PR Newswire)
Jun-07-23 02:00AM	CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress 2023 (PR Newswire)
May-19-23 05:59PM	Why CymaBay Therapeutics Stock Nose-Dived This Week (Motley Fool)
May-16-23 11:06AM	Q1 2023 CymaBay Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.69%
08:50AM	CymaBay Therapeutics Inc. (CBAY) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-15-23 04:04PM	CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
May-10-23 08:00AM	CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 (GlobeNewswire)
May-09-23 08:00AM	CymaBay Names Harish Shantharam Chief Financial Officer (GlobeNewswire)
Apr-28-23 07:00AM	Institutional investors own a significant stake of 45% in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) (Simply Wall St.)
Apr-26-23 10:01AM	Billionaire Joseph Edelman Snaps Up These 2 Biotech Stocks Heres Why You Should Follow (TipRanks)
Apr-21-23 08:00AM	CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) (GlobeNewswire)
Apr-17-23 08:00AM	CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire) +12.12%
Mar-29-23 08:50AM	Here's Why Momentum in CymaBay Therapeutics Inc. (CBAY) Should Keep going (Zacks)
Mar-28-23 09:55AM	Wall Street Analysts Predict a 40.32% Upside in CymaBay Therapeutics Inc. (CBAY): Here's What You Should Know (Zacks)
Mar-20-23 09:04PM	CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-18-23 08:31AM	When Will CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Breakeven? (Simply Wall St.)
Mar-16-23 04:04PM	CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-23 04:05PM	CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023 (GlobeNewswire)
Mar-01-23 08:00AM	CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-06-23 08:00AM	CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-30-23 08:00AM	CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +6.54%
Jan-24-23 07:00AM	CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +15.89%
Jan-23-23 04:11PM	CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-17-23 08:50AM	Here's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price Strength (Zacks)
Jan-08-23 12:00PM	CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis (GlobeNewswire)
Nov-23-22 10:40AM	CymaBay Therapeutics, Inc. (NASDAQ:CBAY) may have lost US$34m in value but insiders who invested last year have seen gains of around US$72k to date (Simply Wall St.)
Nov-17-22 09:40AM	Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-14-22 04:06PM	CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-22 04:05PM	CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022 (GlobeNewswire)
Nov-04-22 08:00AM	CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022 (GlobeNewswire) -5.44%
Nov-03-22 08:00AM	CymaBay Therapeutics to Present at Upcoming Investment Conferences (GlobeNewswire)
Nov-01-22 08:01AM	CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development (GlobeNewswire)
Oct-13-22 09:58AM	Institutional investors own a significant stake of 50% in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) (Simply Wall St.)
Oct-05-22 09:40AM	Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-03-22 08:00AM	CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022 (GlobeNewswire)
Sep-14-22 08:00AM	CymaBay Therapeutics Hosting Virtual Analyst Day on September 22 (GlobeNewswire)
Sep-06-22 08:02AM	CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-05-22 12:00PM	CymaBay Therapeutics Inc. (CBAY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-01-22 10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
09:40AM	Is Swedish Orphan Biovitrum (BIOVF) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-30-22 01:29PM	CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry? (Simply Wall St.) -5.16%
Aug-24-22 08:00AM	CymaBay Therapeutics to Participate in B. Rileys Mini PBC Symposium on August 24, 2022 (GlobeNewswire) +6.07%
Aug-16-22 09:55AM	CymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-12-22 04:30AM	CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript (Motley Fool) +7.22%
Aug-11-22 04:05PM	CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -10.10%
Aug-04-22 04:05PM	CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022 (GlobeNewswire) +5.64%
Aug-02-22 11:17AM	2 Strong Buy Penny Stocks With Substantial Upside Potential (TipRanks) +8.41%
Aug-01-22 08:00AM	CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis (GlobeNewswire)
Jun-22-22 08:00AM	CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress 2022 (GlobeNewswire) +16.50%
Jun-09-22 06:14AM	Trade Alert: The President Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Sujal Shah, Has Just Spent US$100k Buying 43% More Shares (Simply Wall St.)
Jun-08-22 08:00AM	CymaBay Therapeutics Announces Presentations During The International Liver Congress 2022 (GlobeNewswire)
May-23-22 12:43PM	CymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free Survival (Benzinga) -5.71%
08:00AM	CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival (GlobeNewswire)
May-13-22 12:00AM	CymaBay Therapeutics Inc. (CBAY) Q1 2022 Earnings Call Transcript (Motley Fool)
May-12-22 04:06PM	CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-22 08:00AM	CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022 (GlobeNewswire) -8.02%
May-06-22 09:37AM	How Many CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Do Institutions Own? (Simply Wall St.)
May-05-22 04:01PM	CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022 (GlobeNewswire) -9.05%
Apr-24-22 11:05AM	P&G may not be able to continue operations in Russia (American City Business Journals)
Apr-22-22 04:47PM	Barclays Suspends Until Further Notice Further Sales of the iPath ® Series B Bloomberg Natural Gas Subindex Total Return SM ETNs (the "ETNs") (Business Wire)
Apr-20-22 09:26AM	Procter & Gamble beats earnings expectations, raises outlook (Yahoo Finance Video)
07:44AM	P&G CEO doesn't see a recession after big quarter for consumer products giant (Yahoo Finance)
Apr-04-22 08:00AM	CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis (GlobeNewswire)
Mar-23-22 06:13PM	Health Check: How Prudently Does CymaBay Therapeutics (NASDAQ:CBAY) Use Debt? (Simply Wall St.)
Mar-17-22 04:25PM	CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors (GlobeNewswire)
04:06PM	CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-10-22 04:05PM	CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022 (GlobeNewswire)
Feb-10-22 08:00AM	CymaBay Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-24-22 05:38PM	LCM Capital Management Inc Buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Sells ... (GuruFocus.com)
Jan-22-22 06:00AM	Trade Alert: The Chief Medical Officer Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Dennis Kim, Has Just Spent US$61k Buying A Few More Shares (Simply Wall St.)
Jan-11-22 12:00PM	CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jan-04-22 01:38PM	Lvm Capital Management Ltd Buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Sells AT&T Inc, ... (GuruFocus.com)
Dec-16-21 09:14AM	10 Micro-Cap Stocks to Buy According to Hedge Funds (Insider Monkey)
Nov-19-21 09:47AM	7 Penny Stocks With the Potential to 10X in 2022 (InvestorPlace)
Nov-18-21 08:00AM	CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-17-21 04:33PM	CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McWherter Charles	President of R&D	Sep 18	Option Exercise	5.00	21,746	108,730	36,746	Sep 19 05:27 PM
McWherter Charles	President of R&D	Sep 18	Sale	16.22	21,746	352,733	15,000	Sep 19 05:27 PM
Quinlan Paul T	General Counsel	Sep 15	Option Exercise	2.94	53,000	155,820	24,000	Sep 19 05:23 PM
Menold Daniel	Vice President, Finance	Sep 15	Option Exercise	1.73	16,545	28,612	15,000	Sep 19 05:25 PM
Quinlan Paul T	General Counsel	Sep 15	Sale	16.87	53,000	894,141	0	Sep 19 05:23 PM
McWherter Charles	President of R&D	Aug 18	Option Exercise	5.00	21,746	108,730	36,746	Aug 18 07:03 PM
McWherter Charles	President of R&D	Aug 18	Sale	11.47	21,746	249,359	15,000	Aug 18 07:03 PM
Menold Daniel	Vice President, Finance	Aug 15	Option Exercise	5.10	15,500	79,010	8,500	Aug 16 04:59 PM
Quinlan Paul T	General Counsel	Aug 15	Option Exercise	2.94	5,000	14,700	5,000	Aug 16 04:57 PM
Quinlan Paul T	General Counsel	Aug 15	Sale	11.91	5,000	59,550	0	Aug 16 04:57 PM
Menold Daniel	Vice President, Finance	Aug 09	Option Exercise	5.00	20,945	104,725	20,945	Aug 11 06:26 PM
Menold Daniel	Vice President, Finance	Aug 09	Sale	12.35	20,945	258,744	0	Aug 11 06:26 PM
McWherter Charles	President of R&D	Jul 18	Option Exercise	5.00	21,749	108,745	36,749	Jul 19 06:05 PM
McWherter Charles	President of R&D	Jul 18	Sale	11.43	21,749	248,519	15,000	Jul 19 06:05 PM
Quinlan Paul T	General Counsel	Jul 14	Option Exercise	2.94	5,000	14,700	5,000	Jul 14 06:52 PM
Quinlan Paul T	General Counsel	Jul 14	Sale	11.81	5,000	59,050	0	Jul 14 06:52 PM
Quinlan Paul T	General Counsel	Jun 30	Option Exercise	2.94	5,000	14,700	5,000	Jun 30 04:51 PM
Quinlan Paul T	General Counsel	Jun 30	Sale	10.05	5,000	50,250	0	Jun 30 04:51 PM
McWherter Charles	President of R&D	Jun 20	Option Exercise	5.00	21,749	108,745	36,749	Jun 21 06:46 PM
McWherter Charles	President of R&D	Jun 20	Sale	8.16	21,749	177,383	15,000	Jun 21 06:46 PM
McWherter Charles	President of R&D	May 18	Option Exercise	5.00	21,749	108,745	36,749	May 19 06:00 PM
McWherter Charles	President of R&D	May 18	Sale	9.08	21,749	197,387	15,000	May 19 06:00 PM
Quinlan Paul T	General Counsel	May 15	Option Exercise	2.94	5,000	14,700	5,000	May 17 07:11 PM
Quinlan Paul T	General Counsel	May 15	Sale	10.37	5,000	51,831	0	May 17 07:11 PM
KIM DENNIS D	Chief Medical Officer	Apr 17	Option Exercise	4.37	112,219	490,397	132,219	Apr 17 07:24 PM
KIM DENNIS D	Chief Medical Officer	Apr 17	Sale	9.54	112,219	1,070,536	20,000	Apr 17 07:24 PM
KIM DENNIS D	Chief Medical Officer	Apr 13	Option Exercise	4.37	7,781	34,003	27,781	Apr 17 07:24 PM
KIM DENNIS D	Chief Medical Officer	Apr 13	Sale	8.98	7,781	69,880	20,000	Apr 17 07:24 PM
KIM DENNIS D	Chief Medical Officer	Mar 28	Option Exercise	4.37	100	437	20,100	Mar 30 05:39 PM
KIM DENNIS D	Chief Medical Officer	Mar 28	Sale	8.98	100	898	20,000	Mar 30 05:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CBAY | CymaBay Therapeutics, Inc.

Upgrade your FINVIZ experience